What is Wedbush’s Estimate for MLTX Q1 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Wedbush reduced their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Wednesday, February 26th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.76) per share for the quarter, down from their prior estimate of ($0.51). Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at $3.85 EPS.

MLTX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday. The Goldman Sachs Group cut their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Needham & Company LLC lifted their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Buy” and an average price target of $83.20.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ:MLTX opened at $41.76 on Friday. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The stock has a 50-day simple moving average of $46.70 and a 200-day simple moving average of $48.94. The stock has a market capitalization of $2.67 billion, a P/E ratio of -32.37 and a beta of 1.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MLTX. US Bancorp DE acquired a new position in MoonLake Immunotherapeutics during the 3rd quarter valued at about $44,000. Deutsche Bank AG lifted its position in shares of MoonLake Immunotherapeutics by 59.8% in the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock valued at $49,000 after acquiring an additional 338 shares in the last quarter. Birchview Capital LP acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth $217,000. KLP Kapitalforvaltning AS acquired a new stake in MoonLake Immunotherapeutics during the 4th quarter worth about $244,000. Finally, PEAK6 LLC purchased a new position in MoonLake Immunotherapeutics during the fourth quarter valued at approximately $271,000. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.